Abstract
Introduction. Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity. The neurologic toxicity of 5-fluorouracil, the original fluoropyrimidine, including an ataxic cerebellar syndrome is well described. However, only a few case reports exist describing a similar syndrome associated with capecitabine administration.
Case Report. We report a case of reversible cerebellar toxicity during chemotherapy with a combination of capecitabine and oxaliplatin.
Discussion. Rare fluoropyrimide-related toxicities are increasingly being reported in association with capecitabine. Clinical vigilance is required to ensure appropriate investigation and treatment.
Get full access to this article
View all access options for this article.
